Unleashing the TLR9-driven multilineage differentiation of myeloid leukemia cells .
作者信息
Piwocka Katarzyna
机构信息
Nencki Institute of Experimental Biology, Polish Academy of Sciences, Warsaw, Poland.
出版信息
Mol Ther Nucleic Acids. 2025 Jan 2;36(1):102430. doi: 10.1016/j.omtn.2024.102430. eCollection 2025 Mar 11.
Abstract
摘要
相似文献
1
Unleashing the TLR9-driven multilineage differentiation of myeloid leukemia cells .
Mol Ther Nucleic Acids. 2025 Jan 2;36(1):102430. doi: 10.1016/j.omtn.2024.102430. eCollection 2025 Mar 11.
2
Bi-functional CpG-STAT3 decoy oligonucleotide triggers multilineage differentiation of acute myeloid leukemia in mice.
Mol Ther Nucleic Acids. 2024 Jul 16;35(3):102268. doi: 10.1016/j.omtn.2024.102268. eCollection 2024 Sep 10.
3
Acute myeloid leukemia with multilineage dysplasia in children.
Int J Hematol. 2007 Nov;86(4):358-63. doi: 10.1532/IJH97.07025.
4
Interferon-alpha enhances the cytotoxic and cytostatic activities of chemotherapeutic drugs in human myeloid leukemia cells.
J Interferon Cytokine Res. 1996 Feb;16(2):139-46. doi: 10.1089/jir.1996.16.139.
5
Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity.
Blood. 2014 Jan 2;123(1):15-25. doi: 10.1182/blood-2013-07-517987. Epub 2013 Oct 29.
6
TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo.
Blood. 2013 Feb 21;121(8):1304-15. doi: 10.1182/blood-2012-07-442590. Epub 2013 Jan 3.
7
Growth of human myeloid leukemias in the human marrow environment of SCID-hu mice.
Blood. 1993 Oct 15;82(8):2526-36.
8
Lack of Associations between TLR9 and MYD88 Gene Polymorphisms and Risk of Chronic Lymphocytic Leukemia.
Asian Pac J Cancer Prev. 2017 Dec 29;18(12):3245-3250. doi: 10.22034/APJCP.2017.18.12.3245.
9
[Simultaneous occurrence of acute myeloid leukemia with multilineage dysplasia and multiple myeloma].
Rinsho Ketsueki. 2003 Jan;44(1):19-24.
10
The TLR9 agonist (GNKG168) induces a unique immune activation pattern in vivo in children with minimal residual disease positive acute leukemia: Results of the TACL T2009-008 phase I study.
Pediatr Hematol Oncol. 2019 Nov;36(8):468-481. doi: 10.1080/08880018.2019.1667461. Epub 2019 Sep 18.
本文引用的文献
1
Bi-functional CpG-STAT3 decoy oligonucleotide triggers multilineage differentiation of acute myeloid leukemia in mice.
Mol Ther Nucleic Acids. 2024 Jul 16;35(3):102268. doi: 10.1016/j.omtn.2024.102268. eCollection 2024 Sep 10.
2
Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity.
Br J Cancer. 2022 Nov;127(9):1584-1594. doi: 10.1038/s41416-022-01876-6. Epub 2022 Jul 28.
3
Differentiation therapy for myeloid malignancies: beyond cytotoxicity.
Blood Cancer J. 2021 Dec 4;11(12):193. doi: 10.1038/s41408-021-00584-3.
4
Catch me if you can: how AML and its niche escape immunotherapy.
Leukemia. 2022 Jan;36(1):13-22. doi: 10.1038/s41375-021-01350-x. Epub 2021 Jul 23.
5
TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target.
Blood. 2021 Jun 3;137(22):3064-3078. doi: 10.1182/blood.2020005964.
6
Immune escape and immunotherapy of acute myeloid leukemia.
J Clin Invest. 2020 Apr 1;130(4):1552-1564. doi: 10.1172/JCI129204.
7
Myeloid cell-targeted miR-146a mimic inhibits NF-κB-driven inflammation and leukemia progression in vivo.
Blood. 2020 Jan 16;135(3):167-180. doi: 10.1182/blood.2019002045.
8
Targeted Delivery of miRNA Antagonists to Myeloid Cells In Vitro and In Vivo.
Methods Mol Biol. 2019;1974:141-150. doi: 10.1007/978-1-4939-9220-1_10.
9
Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer.
Leukemia. 2018 Aug;32(8):1713-1726. doi: 10.1038/s41375-018-0117-x. Epub 2018 Mar 27.
10
Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.
Nat Med. 2018 May;24(4):450-462. doi: 10.1038/nm.4499. Epub 2018 Mar 5.
Zotero 插件